Annual CFF
$46.00 M
+$45.60 M+11515.15%
December 31, 2023
Summary
- As of February 8, 2025, AVTE annual cash flow from financing activities is $46.00 million, with the most recent change of +$45.60 million (+11515.15%) on December 31, 2023.
- During the last 3 years, AVTE annual CFF has risen by +$37.08 million (+415.77%).
- AVTE annual CFF is now -75.85% below its all-time high of $190.46 million, reached on December 31, 2021.
Performance
AVTE Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$22.00 K
-$24.36 M-99.91%
September 30, 2024
Summary
- As of February 8, 2025, AVTE quarterly cash flow from financing activities is $22.00 thousand, with the most recent change of -$24.36 million (-99.91%) on September 30, 2024.
- Over the past year, AVTE quarterly CFF has dropped by -$441.00 thousand (-95.25%).
- AVTE quarterly CFF is now -99.98% below its all-time high of $128.31 million, reached on September 30, 2021.
Performance
AVTE Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$25.34 M
+$2000.00+0.01%
September 30, 2024
Summary
- As of February 8, 2025, AVTE TTM cash flow from financing activities is $25.34 million, with the most recent change of +$2000.00 (+0.01%) on September 30, 2024.
- Over the past year, AVTE TTM CFF has dropped by -$20.66 million (-44.92%).
- AVTE TTM CFF is now -86.71% below its all-time high of $190.71 million, reached on September 30, 2021.
Performance
AVTE TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
AVTE Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +10000.0% | -95.3% | -44.9% |
| 3 y3 years | +415.8% | -95.3% | -44.9% |
| 5 y5 years | +1739.8% | -95.3% | -44.9% |
AVTE Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -75.8% | >+9999.0% | -100.0% | +108.8% | -86.7% | >+9999.0% |
| 5 y | 5-year | -75.8% | >+9999.0% | -100.0% | +108.8% | -86.7% | >+9999.0% |
| alltime | all time | -75.8% | >+9999.0% | -100.0% | +108.8% | -86.7% | >+9999.0% |
Aerovate Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $22.00 K(-99.9%) | $25.34 M(+0.0%) |
| Jun 2024 | - | $24.38 M(+5076.2%) | $25.33 M(-45.2%) |
| Mar 2024 | - | $471.00 K(+1.7%) | $46.24 M(+0.5%) |
| Dec 2023 | $46.00 M(>+9900.0%) | $463.00 K(+2215.0%) | $46.00 M(+0.2%) |
| Sep 2023 | - | $20.00 K(-100.0%) | $45.89 M(-0.0%) |
| Jun 2023 | - | $45.29 M(>+9900.0%) | $45.91 M(+7316.3%) |
| Mar 2023 | - | $223.00 K(-37.5%) | $619.00 K(+56.3%) |
| Dec 2022 | $396.00 K | $357.00 K(+864.9%) | $396.00 K(-287.7%) |
| Sep 2022 | - | $37.00 K(+1750.0%) | -$211.00 K(-100.2%) |
| Jun 2022 | - | $2000.00(>+9900.0%) | $128.06 M(-29.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $0.00(-100.0%) | $182.57 M(-4.1%) |
| Dec 2021 | $190.46 M(+2035.6%) | -$250.00 K(-100.2%) | $190.46 M(-0.1%) |
| Sep 2021 | - | $128.31 M(+135.4%) | $190.71 M(+167.4%) |
| Jun 2021 | - | $54.51 M(+591.5%) | $71.31 M(+324.5%) |
| Mar 2021 | - | $7.88 M(>+9900.0%) | $16.80 M(+88.4%) |
| Dec 2020 | $8.92 M(+256.7%) | $0.00(-100.0%) | $8.92 M(0.0%) |
| Sep 2020 | - | $8.92 M(>+9900.0%) | $8.92 M(>+9900.0%) |
| Jun 2020 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2020 | - | $0.00 | $0.00 |
| Dec 2019 | $2.50 M | - | - |
FAQ
- What is Aerovate Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Aerovate Therapeutics?
- What is Aerovate Therapeutics annual CFF year-on-year change?
- What is Aerovate Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Aerovate Therapeutics?
- What is Aerovate Therapeutics quarterly CFF year-on-year change?
- What is Aerovate Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Aerovate Therapeutics?
- What is Aerovate Therapeutics TTM CFF year-on-year change?
What is Aerovate Therapeutics annual cash flow from financing activities?
The current annual CFF of AVTE is $46.00 M
What is the all time high annual CFF for Aerovate Therapeutics?
Aerovate Therapeutics all-time high annual cash flow from financing activities is $190.46 M
What is Aerovate Therapeutics annual CFF year-on-year change?
Over the past year, AVTE annual cash flow from financing activities has changed by +$45.60 M (+11515.15%)
What is Aerovate Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of AVTE is $22.00 K
What is the all time high quarterly CFF for Aerovate Therapeutics?
Aerovate Therapeutics all-time high quarterly cash flow from financing activities is $128.31 M
What is Aerovate Therapeutics quarterly CFF year-on-year change?
Over the past year, AVTE quarterly cash flow from financing activities has changed by -$441.00 K (-95.25%)
What is Aerovate Therapeutics TTM cash flow from financing activities?
The current TTM CFF of AVTE is $25.34 M
What is the all time high TTM CFF for Aerovate Therapeutics?
Aerovate Therapeutics all-time high TTM cash flow from financing activities is $190.71 M
What is Aerovate Therapeutics TTM CFF year-on-year change?
Over the past year, AVTE TTM cash flow from financing activities has changed by -$20.66 M (-44.92%)